 UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 12, 2021 GLOBE NEWSWIRE -- Merus N.V. Nasdaq: MRUS, a clinical-stage oncology company developing innovative, full-length multispecific antibodies Biclonics and TriclonicsTM, today announced collaborations with nationwide medical organizations in the Netherlands and Japan to raise awareness of the eNRGy trial and to provide molecular screening opportunities for patients with cancers that may have neuregulin 1 NRG1 fusions. In the collaborations, Merus has agreed to support access to next generation sequencing for eligible patients with pancreatic adenocarcinoma in the Netherlands, and pancreatic adenocarcinoma and non-small cell lung cancer NSCLC in Japan, aimed to identify the presence of NRG1 fusions and raise awareness of potential paths to enrollment in Merus Phase 12 eNRGy trial of bispecific antibody zenocutuzumab Zeno. The collaborating organizations in the two countries are: 